Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations

Area of Science:

• Gynecologic Oncology
• Cancer Genetics
• Population Genetics

Background:

• Fallopian tube carcinoma (FTC) and primary peritoneal carcinoma (PPC) are rare gynecologic malignancies.
• Ashkenazi Jewish (AJ) populations have a higher prevalence of specific BRCA founder mutations.
• Understanding BRCA mutation status in AJ patients with FTC/PPC is crucial for risk assessment and management.

Purpose of the Study:

• To determine the incidence of BRCA mutations in AJ patients diagnosed with FTC or PPC.
• To analyze the clinicopathologic features of these cancers in relation to BRCA mutation status.
• To estimate the cancer risks associated with BRCA mutations in this population.

Main Methods:

• Retrospective review of 51 AJ patients (29 FTC, 22 PPC) across two institutions.
• Genotyping for three common AJ BRCA founder mutations (BRCA1 185delAG, BRCA1 5382insC, BRCA2 6174delT).
• Collection and analysis of surgical, pathological, family history, and survival data.

Main Results:

• Germline BRCA mutations were found in 17% of FTC patients and 41% of PPC patients.
• BRCA mutation carriers were diagnosed at a younger mean age (60 vs. 70 years) and had significantly longer median survival (148 vs. 41 months).
• Estimated lifetime risks for FTC and PPC in BRCA carriers were 0.6% and 1.3%, respectively.

Conclusions:

• A substantial proportion of AJ patients with FTC or PPC carry BRCA mutations.
• BRCA-associated FTC/PPC present with younger age at diagnosis and improved survival outcomes.
• While BRCA heterozygotes have elevated risks compared to the general population, the absolute lifetime risks for FTC/PPC remain relatively low.